Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Genotype-guided comparison of ven-HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: A multicenter real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

YYY. YanHXHan XiaoJZJian Zhang

Discussion

Loading...

Member takes

Overview

Multicenter analysis shows venetoclax improves progression-free survival in acute myeloid leukemia, indicating its efficacy for genotype-sensitive patients.

Key Points

  • VEN/HMA achieved a comparable CRc rate to IC with lower transfusion needs and fewer infections, showing potential benefits for patients.
  • Overall survival improved significantly for intermediate-risk AML patients treated with venetoclax, particularly those with specific mutations.
  • Retrospective analysis of newly diagnosed AML patients across multiple centers informed insights on treatment response and survival.
  • Findings support a genotype-guided approach in acute myeloid leukemia, highlighting the impact of mutation-specific predictors on survival.

Cite This Study

Yan et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d390https://doi.org/10.1182/blood-2025-3452
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent2025
  2. 2Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis2025
  3. 3Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation2025 · 4 citations
  4. 4Efficacy of a venetoclax-based, anthracycline-free regimen in newly diagnosed CBFβ::MYH11(+) acute myeloid leukemia2025
  5. 5Genetic risk stratification in adults with AML receiving venetoclax-based intensive therapy: A real-world study2025